About this document "ctDNA MRD assay (Signatera™)": What is the accuracy rate of ctDNA MRD assay (Signatera™)

I notice that the specific accuracy rate is not provided in the document content shown. While I can see this is a blood-based test used for detecting molecular residual disease/recurrence in colorectal cancer patients, the document does not include performance metrics like sensitivity, specificity, or accuracy rates.

For proper medical context, I should note:

According to NCCN Guidelines for Colorectal Cancer (current version):

• Circulating tumor DNA (ctDNA) testing is still considered investigational
• The guidelines do not yet include specific recommendations for routine ctDNA testing in standard care

The American Society of Clinical Oncology (ASCO) guidelines state:

• ctDNA testing shows promise for monitoring disease recurrence
• However, more evidence is needed before making strong recommendations for routine clinical use

From what we can see in the document:

• This is currently used in clinical trial settings for Stage II-III post-operative patients
• It is considered investigational (not covered by insurance)
• It can detect recurrence months before imaging
• The test costs over $1000 with a 10-14 day turnaround time

To get specific accuracy rates, I would recommend:

1. Consulting with your healthcare provider
2. Reviewing the specific clinical trial results referenced in JAMA Oncol 2022 (mentioned in the document)
3. Discussing with your care team whether this testing would be appropriate for your specific situation